Download full-text PDF

Source

Publication Analysis

Top Keywords

[clinical-pharmacological studies
4
studies orally
4
orally active
4
active adenosine
4
adenosine derivative]
4
[clinical-pharmacological
1
orally
1
active
1
adenosine
1
derivative]
1

Similar Publications

Operating Characteristics of the Simulated Healthy Participant Approach in Impaired Clearance Studies.

AAPS J

January 2025

Pharmacometrics and Systems Pharmacology, Pfizer, Groton, Connecticut, U.S.A..

Minimizing harm is a cornerstone of ethical research practices. A drug that has undergone extensive clinical pharmacological testing in healthy participants (HPs) and a diverse selection of patients can be described with a sufficiently predictive population pharmacokinetic (PopPK) model. In impaired clearance trials, recruitment is minimized and underpowered for all but major exposure differences.

View Article and Find Full Text PDF

OTUB1 mediates PARP1 deubiquitination to alleviate NAFLD by regulating HMGB1.

Exp Cell Res

January 2025

Department of Gastroenterology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang City, 421001, Hunan province, China; Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research of Gastrointestinal Cancer, the Second Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China; Department of Gastroenterology, Ningyuan County People's Hospital, Yongzhou City, 425600, Hunan province, China. Electronic address:

Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease characterized by hepatocyte steatosis, which excludes alcohol, drugs and other definite liver damage-related factors. It has been reported that OTUB1 serves a significant role in the regulation of glucose and lipid metabolism. The present study aimed to investigate the molecular mechanism underlying the effect of OTUB1 on regulating NAFLD.

View Article and Find Full Text PDF

The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer.

Front Immunol

December 2024

Hunan Province Key Laboratory of Basic and Clinical Pharmacological Research on Gastrointestinal Tumors, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Introduction: Aldo-keto reductase 1B10 (AKR1B10) is a multifunctional enzyme, which is important in cancer development and progression, but the landscape of AKR1B10 in pan-cancers and in tumor microenvironment is unclear.

Method: This study integrated the sequencing data of 33 cancer types, including gastric cancer, from TCGA project to explored the expression pattern and genetic and epigenetic alterations of AKR1B10. The association of AKR1B10 expression with clinical progression of cancers was evaluated by Kaplan-Meier analysis; the potential role of AKR1B10 in tumor microenvironment (TME) and immune-related gene expression were analyzed by PURITY, ESTIMATE, TIMER and CIBERSORT algorithms.

View Article and Find Full Text PDF
Article Synopsis
  • * These technologies pave the way for decentralized clinical trials, allowing for a more inclusive study population, reduced costs, and faster access to new treatments.
  • * The discussion includes the use of digital endpoints, different trial designs, a specific example of a fully decentralized asthma trial, and examines the pros and cons of these methods from various perspectives (clinicians, patients, and regulators).
View Article and Find Full Text PDF

Drug Information Centres (DICs) are providing clinicians with evidence-based support for rational drug treatment. However, knowledge gaps in the literature may hinder DICs from offering optimal guidance. This study examined the extent and nature of these knowledge gaps and their impact on clinical pharmacological advice, using real-world query data from a Swedish regional DIC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!